Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - hyaluronic acid, lidocaine - solution for injection - indicated for use in filling of medium size depressions of the skin via mid dermis injection and to create definition and pouting of lips.

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - hyaluronic acid - solution for injection - 20mg/ml

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - hyaluronic acid, lidocaine - solution for injection - injectable gel implant intended to restore the volume of the face. the presence of lidocaine reduces patient pain during the treatment

Новая Зеландия - английский - Medsafe (Medicines Safety Authority)

allergan new zealand ltd - hyaluronic acid, lidocaine - solution for injection - injectable gel implant intended to restore the volume of the face. the presence of lidocaine reduces patient pain during the treatment.

Ирландия - английский - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - trimeprazine tartare - tablets - 10 milligram

Ирландия - английский - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - trimeprazine tartare - syrup - 7.5 mg/5ml

Ирландия - английский - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - trimeprazine tartare - syrup - 30 mg/5ml

Сингапур - английский - HSA (Health Sciences Authority)

allergan singapore pte. ltd. - tazarotene - cream - 0.1% w/w

Сингапур - английский - HSA (Health Sciences Authority)

allergan singapore pte. ltd. - bimatoprost - solution, sterile - 0.3mg/ml

Соединенные Штаты - английский - NLM (National Library of Medicine)

allergan, inc. - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg - kadian is indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use : - because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations [see warnings and precautions ( 5.1 )] , reserve kadian for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. - kadian is not indicated as an as-needed (prn) analgesic. kadian is contraindicated in patients with:  - significant respiratory depression [see warnings and pre cautions ( 5.3 )] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [s ee warnings and precautions ( 5.6 )] - concurrent use